Effect of quercetin on CYP3A activity in chinese healthy participants

Journal of Clinical Pharmacology

Volumn 52, Issue 6, 2012, Pages 940-946

  Duan, Kai Ming ^a   Wang, Sai Ying ^a   Ouyang, Wen ^a   Mao, Yan Mei ^b   Yang, Li Jun ^c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CHANGSHA CENTRAL HOSPITAL   (China)

^c Geological Survey of Hunan Province   (China)

Author keywords

CYP3A; midazolam; quercetin

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; MIDAZOLAM; QUERCETIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; ELECTROPHORESIS; ENZYME ACTIVITY; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ALLELES; CHINA; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DIETARY SUPPLEMENTS; ENZYME INDUCTION; FOOD-DRUG INTERACTIONS; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HALF-LIFE; HUMANS; MALE; METABOLIC DETOXICATION, PHASE I; MIDAZOLAM; POLYMORPHISM, SINGLE NUCLEOTIDE; QUERCETIN; YOUNG ADULT;

EID: 84861798548     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011406278     Document Type: Article

References (24)

1. Ferry DR, Smith A, Malkhandi J, et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res. 1996 ; 2: 659-668
2. Ader P, Wessmann A, Wolffram S. Bioavailability and metabolism of the flavonol quercetin in the pig. Free Radic Biol Med. 2000 ; 28: 1056-1067
3. Murray MT. Quercetin: nature's antihistamine. Better Nutr. 1990 ; 60: 10
4. Lamson DW, Brignall MS. Antioxidants and cancer III: quercetin. Alternat Med Rev. 2000 ; 5: 196-208
5. Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, Watkins PB. The human CYP3A subfamily: practical considerations. Drug Metab Rev. 2000 ; 32: 339-361
6. Shih PS, Huang JD. Pharmacokinetics of midazolam and 1a-hydroxy-midazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos. 2002 ; 30: 1491-1496
7. Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis. 2004 ; 8: 67-81
8. Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 1996 ; 59: 491-502
9. Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 ; 16: 408-414
10. Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther. 2002 ; 72: 474-489
11. Zhu YP, Jin NZ, Zhou JW, Mao L, Zhao RC, Tong J. Effect of quercetin on the activities of cytochrome p450 1A1 in L-02 cell lines and human liver microsomes [in Chinese]. Zhonghua Gan Zang Bing Za Zhi. 2005 ; 13: 233-234
12. Tang WB, Ma PQ, Ni H, Zeng WT, Zhu KL. Expression of HSP70 and P-glycoprotein (P-gp) in human hepatocarcinoma HepG2 cells induced by heat shock and inhibiting effect of quercetin on them. Ai Zheng. 2003 ; 22: 954-958
13. Hsiu SL, Hou YC, Wang YH, Tsao CW, Su SF, Chao PD. Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sci. 2002 ; 72: 227-235
14. He N, Edeki T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther. 2004 ; 11: 206-212
15. Ho PC, Saville DJ, Wanwimolruk S. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci. 2001 ; 4: 217-227
16. Ma HW, Cheng J, Caddy B. Extraction of high quality genomic DNA from microsamples of human blood. J Forensic Sci Soc. 1994 ; 34: 231-235
17. Liu TC, Lin SF, Chen TP, Chang JG. Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncol Rep. 2002 ; 9: 327-329
18. Song X, Xie M, Zhang H, Li Y, Sachdeva K, Yan B. The pregnane X receptor binds to response elements in a genomic context-dependent manner, and PXR activator rifampicin selectively alters the binding among target genes. Drug Metab Dispos. 2004 ; 32: 35-42
19. Moore JT, Kliewer SA. Use of the nuclear receptor PXR to predict drug interactions. Toxicology. 2000 ; 153: 1-10
20. Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ. Expression of CYP3A, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocyte. J Biol Chem. 2002 ; 277: 25125-25132
21. Moore LB, Goodwin B, Jones SA, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A. 2000 ; 97: 7500-7502
22. Sahi J, Milad MA, Zheng X, et al. Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor. J Pharmacol Exp Ther. 2003 ; 306: 1027-1034
23. Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther. 2001 ; 299: 849-857
24. Hashida T, Masuda S, Uemoto S, Saito H, Tanaka K, Inui K. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther. 2001 ; 69: 308-316